Stevens-Johnson syndrome and toxic epidermal necrolysis: What do we know?

Alfredo Tartarone, Rosa Lerose

Research output: Contribution to journalArticlepeer-review


Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are rare but severe cutaneous adverse reactions related to a variety of medications. Although rare, SJS and TEN have a significant impact on public health because of high mortality. Also, if the SJS/TEN physiopathology is still unclear, a specific immune response to one or more drugs is involved, constituting a form of delayed-type hypersensitivity. Patients with SJS/TEN are often critically ill; therefore, they must be admitted to hospitals capable of delivering critical care. Currently, no treatment modality has been established as standard for these patients; therefore, therapy is primarily supportive and symptomatic and involves a multidisciplinary approach.

Original languageEnglish
Pages (from-to)669-672
Number of pages4
JournalTherapeutic Drug Monitoring
Issue number6
Publication statusPublished - Dec 2010


  • drug interaction
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'Stevens-Johnson syndrome and toxic epidermal necrolysis: What do we know?'. Together they form a unique fingerprint.

Cite this